- First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basis
- First quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81
- Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals
WARSAW, Ind., May 5, 2025 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025. The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% over the prior year period, and an increase of 2.3% on a constant currency1 basis. Net earnings for the first quarter were $182.0 million, or $361.1 million on an adjusted1 basis.
Diluted earnings per share were $0.91 for the first quarter, and adjusted1 diluted earnings per share were $1.81.
| 1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. | ||||
“We are proud of our team’s continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda,” said Ivan Tornos, Zimmer Biomet’s President and Chief Executive Officer. “We’re excited about the momentum in U.S. Hips, fueled by our revamped portfolio inclusive of the Z1™ Triple-Taper Femoral Hip System, HAMMR® Automated Hip Surgical Impactor System, as well as navigation capabilities, and believe the early enthusiasm from surgeons for our new Oxford® Cementless Partial Knee positions us well to accelerate growth in the second half of the year. The recently completed acquisition of Paragon 28 is another bold step toward our innovation and diversification ambitions, expanding our S.E.T. business with leading technologies and a dedicated commercial channel in the high-growth foot and ankle segment.”
Recent Highlights
- Completed the acquisition of Paragon 28, Inc., a leading medical device company focused exclusively on the foot and ankle orthopedic segment, further strengthening Zimmer Biomet’s position in this high-growth space.
- Showcased a broad portfolio of innovations at the 2025 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, including a comprehensive hip portfolio anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key robotic solutions. In addition, Zimmer Biomet debuted ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint.
- Received U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals. The product will be commercially available in the U.S. in Q3 2025.
- Launched the You’ll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger, providing millions of people living with joint pain with an online community that empowers them with resources to make informed choices about their mobility.
- Announced upcoming changes to Zimmer Biomet’s Board of Directors, effective at the Company’s annual meeting of stockholders on May 29, 2025, including the retirement of Non-Executive Chairman Christopher Begley; the appointment of President and CEO Ivan Tornos as Chairman of the Board upon Mr. Begley’s retirement; and the naming of Michael Farrell as Lead Independent Director upon Mr. Begley’s retirement.
- Appointed Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer, and Kristen Cardillo as Senior Vice President, Chief Communications Officer, to the Zimmer Biomet Executive Leadership Team.
- Named one of the 2025 World’s Most Ethical Companies® by Ethisphere.
Geographic and Product Category Sales
The following sales table provides results by geography and product category for the three-month period ended March 31, 2025, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis.
